Preemptive rituximab therapy is used in patients at high risk of TTP relapse, like patients after remission with persistently low ADAMTS13 activity [89], to minimize the relapse rate by up to 75% [90]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.